Can Aspect Biosystems turn government-backed biomanufacturing into a real regenerative medicine advantage?
Aspect Biosystems has secured a $280 million Canada-backed push in regenerative medicine. Read what it means for cellular therapy scale-up.
Pharma & Biotech